Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers

Jong Kee Kim, Hyeon Ji Lee, Young Jo Lee, Jong Yoon Chun, In Kyoung Lee, Young Suk Lim, Dong Jin Suh, Sun-Young Ko, Myeong Hee Kim, Heung Bum Oh

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Mutations in the YMDD motif of the hepatitis B virus (HBV) polymerase gene increase lamivudine resistance of HBV, highlighting the clinical importance of accurate and sensitive detection of HBV mutants. Using dual-priming oligonucleotide primer technology, an assay that can detect mutations at codons 180 (L528M) and 204 (YVDD, YIDD, and YSDD) by a single-step multiplex PCR was developed. This Seeplex Lami-DR assay was sufficiently sensitive to detect 103 HBV/ml and was able to detect minor mutants comprising as little as 2% of the viral population. Mutants were detected in 57 of 65 serum samples (88%) from patients with chronic hepatitis B who had been treated with lamivudine (median, 32 months; range, 1-83 months). The agreement with direct sequencing was only 38.5% (25/65). Discrepancies between these methods resulted from detection of additional mutants by the Seeplex Lami-DR assay, as confirmed by a novel verification analysis. This assay is not only highly accurate and sensitive, but is also simple and cost-effective, requiring no expensive probes, laborious sequencing procedures, or digestion with restriction enzymes. Accordingly, the Seeplex HBV Lami-DR assay should be considered as a first-line, cost-effective tool for detecting viral mutations in patients with chronic hepatitis B receiving lamivudine therapy.

Original languageEnglish
Pages (from-to)76-84
Number of pages9
JournalJournal of Virological Methods
Volume149
Issue number1
DOIs
Publication statusPublished - 2008 Apr 1
Externally publishedYes

Fingerprint

DNA Primers
Lamivudine
Multiplex Polymerase Chain Reaction
Hepatitis B virus
Chronic Hepatitis B
Mutation
Costs and Cost Analysis
Codon
Digestion
Technology
Enzymes
Serum
Population
Genes

Keywords

  • Chronic hepatitis B
  • HBV
  • Lamivudine resistance
  • Seeplex Lami-DR assay

ASJC Scopus subject areas

  • Virology

Cite this

Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers. / Kim, Jong Kee; Lee, Hyeon Ji; Lee, Young Jo; Chun, Jong Yoon; Lee, In Kyoung; Lim, Young Suk; Suh, Dong Jin; Ko, Sun-Young; Kim, Myeong Hee; Oh, Heung Bum.

In: Journal of Virological Methods, Vol. 149, No. 1, 01.04.2008, p. 76-84.

Research output: Contribution to journalArticle

Kim, Jong Kee ; Lee, Hyeon Ji ; Lee, Young Jo ; Chun, Jong Yoon ; Lee, In Kyoung ; Lim, Young Suk ; Suh, Dong Jin ; Ko, Sun-Young ; Kim, Myeong Hee ; Oh, Heung Bum. / Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers. In: Journal of Virological Methods. 2008 ; Vol. 149, No. 1. pp. 76-84.
@article{5e62381e0bb941dfa79516c30908dd52,
title = "Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers",
abstract = "Mutations in the YMDD motif of the hepatitis B virus (HBV) polymerase gene increase lamivudine resistance of HBV, highlighting the clinical importance of accurate and sensitive detection of HBV mutants. Using dual-priming oligonucleotide primer technology, an assay that can detect mutations at codons 180 (L528M) and 204 (YVDD, YIDD, and YSDD) by a single-step multiplex PCR was developed. This Seeplex Lami-DR assay was sufficiently sensitive to detect 103 HBV/ml and was able to detect minor mutants comprising as little as 2{\%} of the viral population. Mutants were detected in 57 of 65 serum samples (88{\%}) from patients with chronic hepatitis B who had been treated with lamivudine (median, 32 months; range, 1-83 months). The agreement with direct sequencing was only 38.5{\%} (25/65). Discrepancies between these methods resulted from detection of additional mutants by the Seeplex Lami-DR assay, as confirmed by a novel verification analysis. This assay is not only highly accurate and sensitive, but is also simple and cost-effective, requiring no expensive probes, laborious sequencing procedures, or digestion with restriction enzymes. Accordingly, the Seeplex HBV Lami-DR assay should be considered as a first-line, cost-effective tool for detecting viral mutations in patients with chronic hepatitis B receiving lamivudine therapy.",
keywords = "Chronic hepatitis B, HBV, Lamivudine resistance, Seeplex Lami-DR assay",
author = "Kim, {Jong Kee} and Lee, {Hyeon Ji} and Lee, {Young Jo} and Chun, {Jong Yoon} and Lee, {In Kyoung} and Lim, {Young Suk} and Suh, {Dong Jin} and Sun-Young Ko and Kim, {Myeong Hee} and Oh, {Heung Bum}",
year = "2008",
month = "4",
day = "1",
doi = "10.1016/j.jviromet.2008.01.003",
language = "English",
volume = "149",
pages = "76--84",
journal = "Journal of Virological Methods",
issn = "0166-0934",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers

AU - Kim, Jong Kee

AU - Lee, Hyeon Ji

AU - Lee, Young Jo

AU - Chun, Jong Yoon

AU - Lee, In Kyoung

AU - Lim, Young Suk

AU - Suh, Dong Jin

AU - Ko, Sun-Young

AU - Kim, Myeong Hee

AU - Oh, Heung Bum

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Mutations in the YMDD motif of the hepatitis B virus (HBV) polymerase gene increase lamivudine resistance of HBV, highlighting the clinical importance of accurate and sensitive detection of HBV mutants. Using dual-priming oligonucleotide primer technology, an assay that can detect mutations at codons 180 (L528M) and 204 (YVDD, YIDD, and YSDD) by a single-step multiplex PCR was developed. This Seeplex Lami-DR assay was sufficiently sensitive to detect 103 HBV/ml and was able to detect minor mutants comprising as little as 2% of the viral population. Mutants were detected in 57 of 65 serum samples (88%) from patients with chronic hepatitis B who had been treated with lamivudine (median, 32 months; range, 1-83 months). The agreement with direct sequencing was only 38.5% (25/65). Discrepancies between these methods resulted from detection of additional mutants by the Seeplex Lami-DR assay, as confirmed by a novel verification analysis. This assay is not only highly accurate and sensitive, but is also simple and cost-effective, requiring no expensive probes, laborious sequencing procedures, or digestion with restriction enzymes. Accordingly, the Seeplex HBV Lami-DR assay should be considered as a first-line, cost-effective tool for detecting viral mutations in patients with chronic hepatitis B receiving lamivudine therapy.

AB - Mutations in the YMDD motif of the hepatitis B virus (HBV) polymerase gene increase lamivudine resistance of HBV, highlighting the clinical importance of accurate and sensitive detection of HBV mutants. Using dual-priming oligonucleotide primer technology, an assay that can detect mutations at codons 180 (L528M) and 204 (YVDD, YIDD, and YSDD) by a single-step multiplex PCR was developed. This Seeplex Lami-DR assay was sufficiently sensitive to detect 103 HBV/ml and was able to detect minor mutants comprising as little as 2% of the viral population. Mutants were detected in 57 of 65 serum samples (88%) from patients with chronic hepatitis B who had been treated with lamivudine (median, 32 months; range, 1-83 months). The agreement with direct sequencing was only 38.5% (25/65). Discrepancies between these methods resulted from detection of additional mutants by the Seeplex Lami-DR assay, as confirmed by a novel verification analysis. This assay is not only highly accurate and sensitive, but is also simple and cost-effective, requiring no expensive probes, laborious sequencing procedures, or digestion with restriction enzymes. Accordingly, the Seeplex HBV Lami-DR assay should be considered as a first-line, cost-effective tool for detecting viral mutations in patients with chronic hepatitis B receiving lamivudine therapy.

KW - Chronic hepatitis B

KW - HBV

KW - Lamivudine resistance

KW - Seeplex Lami-DR assay

UR - http://www.scopus.com/inward/record.url?scp=40849101514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40849101514&partnerID=8YFLogxK

U2 - 10.1016/j.jviromet.2008.01.003

DO - 10.1016/j.jviromet.2008.01.003

M3 - Article

VL - 149

SP - 76

EP - 84

JO - Journal of Virological Methods

JF - Journal of Virological Methods

SN - 0166-0934

IS - 1

ER -